RismadarVoice Reporters
October 7, 2026
President Donald Trump’s claim that Americans are now paying the world’s lowest prescription drug prices is facing scrutiny after an independent analysis found significant differences between prices available through TrumpRx and those in other wealthy countries.
Trump has promoted TrumpRx as a major part of his administration’s efforts to reduce prescription medicine costs, arguing that agreements reached with pharmaceutical companies are bringing US prices closer to, or below, those available elsewhere.
However, an analysis by health policy organisation KFF found that TrumpRx prices were lower than the average publicly listed prices in comparable countries for 17 of 32 brand-name medicines examined.
For the remaining 15 medicines, TrumpRx prices were higher than the average among the countries studied.
Only five of the 32 medicines had TrumpRx prices lower than those available in every other country included in the comparison. By contrast, 13 had TrumpRx prices higher than those available in all the other countries where comparable pricing information was available.
The findings suggest that the impact of the programme varies considerably depending on the medicine.
For Enbrel, which is used to treat inflammatory conditions including rheumatoid arthritis, the TrumpRx price was $3,354, compared with an average of $641 among the other countries examined.
Overall, nine medicines analysed by KFF were priced at least twice as high through TrumpRx as the average price in the comparison countries.
Other medicines, however, were available at substantially lower prices through the US platform, highlighting the uneven nature of the programme’s discounts.
KFF examined brand-name medicines listed on TrumpRx that did not have generic or biosimilar alternatives available in the United States and for which comparable public pricing information could be obtained from at least one of 11 other developed economies.
Those countries included Australia, Austria, Belgium, Canada, France, Germany, Japan, the Netherlands, Sweden, Switzerland and the United Kingdom.
The analysis also cautioned that international drug-price comparisons have limitations.
Publicly available prices in other countries may not reflect the actual amount paid by patients, while governments and health systems can negotiate confidential discounts that are not captured in published figures.
The comparison also does not establish whether prices in the United States fell as a direct result of the Trump administration’s agreements with pharmaceutical companies.
TrumpRx was launched in February as a government platform providing consumers with access to discounted prescription medicines. For many products, it directs cash-paying consumers to manufacturers’ discount programmes rather than selling medicines directly.
The administration has pursued voluntary pricing agreements with pharmaceutical manufacturers as part of its broader effort to link some US medicine prices more closely with those paid in other developed countries.
The latest findings do not show that TrumpRx prices are uniformly higher internationally. Instead, they indicate that the administration’s broader claim of delivering the world’s lowest prescription drug prices does not apply consistently across the medicines examined.
The debate over prescription drug costs is expected to remain prominent in the United States as the administration continues to defend its pricing policies and expands efforts to reduce medicine costs.
